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Background: The GAVI Alliance’s decision in late 2011 to invite developing countries to apply for funding for
human papillomavirus (HPV) vaccine introduction underscores the importance of understanding levels of HPV
vaccine acceptance in developing country settings. In this paper, we present findings from qualitative research on
parents’ rationales for vaccinating or not vaccinating their daughters (vaccine acceptance) and their decision-
making process in the context of an HPV vaccination demonstration project in Vietnam (2008–2009).
Methods: We designed a descriptive qualitative study of HPV vaccine acceptability among parents of girls eligible
for vaccination in four districts of two provinces in Vietnama. The study was implemented after each of two years of
vaccinations was completed. In total, 133 parents participated in 16 focus group discussions and 27 semi-structured
interviews.
Results: Focus group discussions and in-depth interviews with parents of girls vaccinated revealed that they were
generally very supportive of immunization for disease prevention and of vaccinating girls against HPV. The
involvement of the National Expanded Program of Immunization in the demonstration project lent credibility to the
HPV vaccine, contributing to high levels of acceptance. For parents who declined participation, concerns about side
effects, the possibility that the vaccine was experimental, and the possible impact of the vaccine on future fertility
rose to the surface. In terms of the decision-making process, many parents exhibited ‘active decision-making,’
reaching out to friends, family, and opinion leaders for guidance prior to making their decision.
Conclusion: Vietnam’s HPV vaccination experience speaks to the importance of close collaboration with the
government to make the most of high levels of trust, and to reduce suspicions about new vaccines that may arise
in the context of vaccine introduction in developing country settings.
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The burden of mortality from cervical cancer falls dispro-
portionately upon women living in the developing world,
where 88% of deaths from cervical cancer occur [1]. Cer-
vical cancer is the second most common form of cancer
among women in the developing world and the leading
cause of cancer mortality for women. While cancer mortal-
ity has declined in high-income countries with improved
screening and treatment services, the incidence of cervical
cancer is projected to increase in middle- and low- income
countries as their populations grow and age. By 2030, these
countries will be home to an estimated 98% of cervical
cancer deaths [1].
In light of the difficulty and cost of introducing effective
and widespread screening services in low-resource set-
tings, successful production of cervical cancer vaccines
constitutes an important advancement for women's
health. Currently, there are two vaccines—Merck’s Garda-
silW and GlaxoSmithKline’s CervarixW—that are highly ef-
fective in protecting against the strains of human
papillomavirus (HPV) that cause 70% of cervical cancers.
These vaccines have been licensed in more than 100 coun-
tries and, by the close of 2010, introduced in 33 national
health programs. Though most of these national programs
are in high-income countries, 20 developing countries
have undertaken pilot projects to test the feasibility of
introducing HPV vaccine on a national scale [2]. One such
country, Vietnam, began testing strategies for HPV vac-
cine delivery in 2008, collecting data on coverage, accept-
ability, feasibility, and costs associated with integrating
HPV vaccine into their National Expanded Program on
Immunization (NEPI).
In low-resource settings, many factors influence the
decision of whether and how to integrate a new vac-
cine into a national health program. Policymakers are
increasingly asking for evidence of the impact a new
vaccine is likely to have on communities as well as
on the health care delivery system [3-5]. Based on re-
search conducted in Latin America, Winkler et al.
identified five distinct factors that shape the decision
to introduce cervical cancer vaccines into public sec-
tor health programs: knowledge of cervical cancer in-
cidence and its connection to HPV; affordability
considerations; political will in the context of compet-
ing interests; the feasibility of vaccine delivery; and
vaccine acceptability in the community [6]. It is this
last decision-making factor—acceptability—that is the
focus of this paper. As part of their decision-making
process, policymakers want to know whether the vac-
cine will be accepted by those communities that will
benefit, whether local opinion leaders will be support-
ive of a new vaccine, and whether support has been
garnered among health providers who are asked to
promote and deliver the new vaccine [7,8].In a recent literature review of studies exploring
factors affecting HPV vaccine acceptance among adult
women considering vaccination for themselves, Black
et al. observed that the extent of knowledge of HPV
infection and its connection to cervical cancer, the
perception of risk for HPV infection or cervical can-
cer, the cost of the vaccine, and misinformation about
HPV vaccine were all factors associated with vaccine
acceptability for adult women [9]. Although the indi-
vidual studies differ in methodology and focus, the
main conclusion was that women generally were re-
ceptive toward HPV vaccine. An important caveat is
that this review focused on studies of HPV vaccine
acceptance in industrialized settings.
Far fewer studies address acceptability in developing
country settings, prompting a call for further research
[10]. A systematic review of HPV acceptability in nine
countries in Asia Pacific included studies from India, Ma-
laysia, Vietnam, Taiwan, Thailand, and South Korea (as
well as Australia, New Zealand, and China) [11]. Despite
the wide variation in methodology and approach, accept-
ability factors that emerged across a multitude of studies
include perceived susceptibility to HPV (eight studies),
perceived safety and side effects of the vaccine (twelve
studies), concerns over effects on fertility (three studies),
efficacy of the vaccine (six studies), and HPV vaccine
recommendation by physician or social referent (seven
studies). Research from Uganda presented similar areas of
concern from parents [12], suggesting that motivating fac-
tors for parents related to HPV vaccine acceptance may be
more universal than previously thought.
However, previous studies, including the reviews
cited above, focus on “intent to vaccinate” prior to
HPV vaccine availability or introduction. In Vietnam,
we had the opportunity to examine parents’ rationales
for either having or not having their daughters vacci-
nated and their decision-making process in the con-
text of an on-going HPV vaccination demonstration
project. This project, implemented by the National
Institute for Hygiene and Epidemiology (NIHE), was
designed to identify appropriate strategies for HPV
vaccine delivery that could be integrated into NEPI. It
targeted girls in grade 6 or 11 years old in four dis-
tricts of two provinces, spanning urban, rural, and
mountainous areas. The districts were selected based
on cervical cancer disease burden, population size,
geography, socioeconomic status, EPI performance,
and staff capacities.
Most research on vaccine acceptability utilized a single
type of measurement in exploring vaccine acceptability,
often either a yes/no question [13,14] or multiple items
with a Likert scale [15-18]. Measures derived solely from
quantitative survey data may not be sufficient for under-
standing the many facets of acceptability [19] and these
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qualitative approaches. In this article, we present findings
from qualitative research on parental reasons for HPV
vaccine acceptance/non-acceptance and their decision-
making process after both the first and second year of
HPV vaccine implementation in Vietnam, and
contextualize these qualitative data with recently pub-
lished quantitative data on vaccine acceptability from this
same project [20].
Methodsd
We designed a descriptive qualitative study of HPV vac-
cine acceptability among parents of girls eligible for vac-
cination in four districts of two provinces in Vietnam.a
Eligible girls for HPV vaccination were either 11 years of
age (for the health-center based delivery strategy) or in
grade 6 of primary school (for the school-based delivery
strategy), of which more than 80% were 11 years of age,
approximately 13% were 10 years old, and the remaining
were 12 years old [20]. The study was implemented after
the first year of vaccinations ended in June 2009 and
repeated after the second year of vaccinations was com-
pleted in April 2010.
We used focus group discussions (FGD) and semi-
structured interviews (SSI) to explore reasons for HPV
vaccine acceptance or non-acceptance as well as to as-
certain the process by which parents make their deci-
sion. FGDs were conducted with parents of fully
vaccinated girls. Due to the very small number of girls
who were partially vaccinated and the concentration of
non-vaccinated girls in one urban location where
school-based delivery was implemented,b SSIs were con-
ducted with parents of non- or partially-vaccinated girls.
Additionally, in the Vietnamese context, not participat-
ing in a community-based vaccination program may
have resulted in feelings of stigmatization among par-
ents, inhibiting discussion of the reasons for their deci-
sion in a group setting. Individual interviews with these
parents provide a more neutral, non-threatening envir-
onment to explore their decision. The key areas of
inquiry included in the FGD guide and the SSI question-
naire were the same for both groups of parents. Key
themes to elicit information about vaccine acceptability
and the decision-making process were explored through
a series of open-ended questions; some examples are
provided below.
Questions for FGDs:
 What factors (personal, family, community,
information, communication strategy) or individuals
influenced your decision to have your daughter
vaccinated?
 Please tell me how you made the decision about
your daughter’s vaccination. Who raised the issue ofHPV vaccination first, then who said what, and, who
gave the final decision? Who, if anyone, did you
discuss this with?
 Did anyone help you decide on whether to have
your daughter vaccinated? Who influenced, why,
how, and when?
Questions for SSIs:
 Why did your daughter not receive the full three
doses?
 Were there any concerns that you had that kept you
from taking your daughter (back) for vaccination?
 Please tell me how you made the decision about
your daughter’s vaccination. Who raised the issue of
HPV vaccination first, then who said what, and, who
gave the final decision? Who, if anyone, did you
discuss this with?
 Did anyone help you decide on whether to have
your daughter vaccinated? Who influenced, why,
how, and when?Sampling process
The sampling process for study areas and populations
varied from the first and second years of our study. As
no study had yet been done of HPV vaccine acceptability
after implementation of a HPV vaccination program, we
selected a wide range of areas and large number of parti-
cipants for our study after the first year of vaccinations.
We performed criteria-based sampling for study areas
using HPV vaccine delivery strategy implemented, type
of geography (urban, rural, mountainous), and estimates
of HPV vaccine uptake from NEPI reports. We used
communes, administrative boundaries for health and
other services in Vietnam, as the demarcation for study
areas. All 72 communes that participated in the first year
of the HPV vaccination program were classified by deliv-
ery strategy, type of geography, and low- or high-uptake
based on NEPI reports (Figure 1). In each “geography-
strategy” stratum, the three communes having the lowest
uptake and the three with the highest were included in
the sampling frame. From each group of three, one was
randomly selected. The final sampling frame included 12
communes: ten communes had one FGD with parents of
girls who received all three doses of HPV vaccine (fully
vaccinated); and two communes with low uptake had
SSIs with parents of girls who either were not vaccinated
or received less than three doses (partially vaccinated).
The rationale for sampling in this fashion was to ensure
the inclusion of a range of different types of communes
to reflect the geographic diversity of the country and the
infrastructure capacities of communes that delivered
HPV vaccines.
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Figure 1 Sampling frame for acceptability by geographic area, strategy, and commune, Year 1.
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tions was different, as nearly all 72 communes had
achieved high uptake during the second year of program
implementation and there was a purposive attempt to
oversample communes where vaccine uptake was the low-
est. Again using communes as the area of study and strati-
fying by delivery strategy, in mountainous areas, we used
geographic access as a selection criteria for identifying one
‘easy to reach’ commune (less than ten kilometers from
district center) from the school-based delivery strategy
and one ‘hard to reach’ commune (more than 40 kilo-
meters from district center) from the health center-based
delivery strategy out of a total of 18 communes. In rural
areas, we randomly selected two communes (from a total
of 33 communes), one from each delivery strategy, from a
list of seven that did not report 100% HPV vaccinationRural  













Low uptake  
n = 2 
Low uptake  
n = 1 
Figure 2 Sampling frame for acceptability by geographic area, strateuptake at dose two. In urban areas, two communes (from
a total of 21 communes), one from each delivery strategy,
were purposively selected based on the highest reported
number of girls not vaccinated at dose two (Figure 2). An
additional commune with the lowest vaccine uptake dur-
ing the first year of implementation from the school-based
delivery strategy was added to the sampling frame for par-
ents of partially/non-vaccinated girls to investigate
changes in this area over time (not included in Figure 2).
The final sampling frame included seven communes, six
of which had one FGD each with parents of fully vacci-
nated girls and the seventh had parents of partially/non-
vaccinated girls who were selected for a SSI. This sam-
pling strategy allowed us to focus in on any regional differ-
ences, as well as to highlight reasons for non-acceptance
of HPV vaccination.Mountainous 
N = 21 
School-based  
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gy, and commune, Year 2.
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For all FGDs with parents of fully vaccinated girls, we
used a purposive selection process to ensure a diver-
sity of voices invited to participate in our study. Par-
ents of fully vaccinated girls were selected by research
staff from a list compiled by health workers, following
the third dose of vaccination. Each FGD could ac-
commodate ten to twelve participants. Similarly, parti-
cipants in SSIs were selected from a list of partially/
non-vaccinated girls.
After the research staff selected parents to invite to
the FGD, they were contacted by commune health
workers through household visits, given the invitation
to participate, and informed of the date, time, and
venue for the FGD. The same procedure was followed
to invite parents of partially/non-vaccinated girls to a
SSI. The final sample included 133 parents of girls
eligible for HPV vaccination from 19 communes
(Table 1), approximately two-thirds were mothersc.
Data collection, management, and analysis
Data were collected within two months of the last
HPV vaccination session in each year of the program.
All FGDs and SSIs were conducted in Vietnamese
and tape recorded. Two members of the research
team took part, with one serving as facilitator and the
other as note taker. Notes taken during the discussion
were used for reference and comparison during ana-
lysis. All tape recordings of FGDs and SSIs were tran-
scribed. The unit of analysis was the parent.
Transcriptions were compared with notes taken dur-
ing the discussion/interview as a preliminary data ana-
lysis stage to develop a standardized coding scheme
[21,22]. NVivo electronic textual management software
was used to organize, sort, and synthesize information
into textual matrices based on the coding scheme devel-
oped for analysis and interpretation [23,24].
Both inductive and deductive analysis processes
linked codes (representing key themes) to research
questions. Multiple iterations of data synthesis, inter-
pretation, and summarization were carried out. Using
a reflective process, each iteration included a critical
review of the data for emerging findings to furtherTable 1 Study population, data collection method, and samp
2009–2010
Study population
Year 1 Parents of fully vaccinated girls
Parents of partially or non-vaccinated girls
Year 2 Parents of fully vaccinated girls
Parents of partially or non-vaccinated girls
Total
FGD focus group discussion; SSI semi-structured interview.verify the data findings, followed by further refine-
ment and synthesis of data [22]. This iterative process
continued throughout the analysis.
Quality control procedures were implemented at
several stages during data collection, management,
and analysis. Research teams were comprised of two
interviewers who compared notes and initial impres-
sions after each FGD or SSI was completed. A stan-
dardized coding scheme of transcribed data ensured
consistency in data organization and management,
and facilitated a systematic approach to the data ana-
lysis to keep focused on the study objectives [22].
Validation of coding assignments on a random sample
of FGDs by an independent qualitative researcher not
directly involved in the data collection was also con-
ducted to verify accuracy of coding by the research
team.
Ethics approvals
Verbal consent was a prerequisite for parents’ involve-
ment, both for focus group participation and in the SSIs.
A member of the research team served as a consent wit-
ness for parents. The research team explained to partici-
pants the purpose of the research, how they were invited,
and the voluntary nature of their participation. No parent
invited to participate refused. We do not have any reason
to believe that our subjects were unusual in some way;
however, purposive sampling techniques are not the same
as random sampling and may not be representative of the
entire population of parents whose daughters were eligible
for HPV vaccine during the two-year program.
Our study was approved by the Research Ethics
Committee at PATH (USA) and the Institutional Re-




Perception of risks and health benefits
Parents reflected on the success of vaccinations in Viet-
nam in general, with a focus on disease prevention more
broadly. As the following quote suggests, some parents
participated in the HPV vaccination program less out ofle size for acceptability study, HPV vaccines, Vietnam,
Data collection method Sample size
10 FGDs (10 communes) 64
24 SSIs (2 communes) 24
6 FGDs (6 communes) 42
3 SSIs (1 commune) 3
16 FGDs and 27 SSIs 133 parents
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from a conviction that vaccination itself is beneficial:
“. . .Immunization is the best way of prevention.
Whatever disease like tuberculosis or measles,
immunization is the best. Prevention is better than
treatment.”
– Parent of fully vaccinated girl, FGD, Year 1, Rural,
low uptake commune
Others voiced health rationales that were specific to
fears of cervical cancer:
“I was advised by the doctor so I took the girl to get
vaccination. It is because I saw many people had that
awful disease. Most patients with cancer do not
survive. That’s what I heard. I also knew that
vaccination can prevent the disease ; that is why when
hearing about vaccination, I was very happy.”
– Parent of fully vaccinated girl, FGD, Year 2, Urban,
low uptake commune
Although health benefits were offered as a reason
among participants across all regions, in focus groups in
urban areas parents tended to specifically emphasize this
point, confirming the importance of vaccination in pre-
venting disease.
Trust in governmental program
Focus group findings also suggested that people were
influenced by knowledge that the campaign was a
publicly-implemented program, their reasoning
grounded in a belief that “government cannot harm
people’s health” with the introduction of a given
health service or new vaccine.
“Firstly, it is a government program. Secondly, it is the
responsibility of all parents. Those reasons are enough
to decide.”
– Parent of fully vaccinated girl, FGD, Year 1, Rural,
low uptake commune
This kind of statement was more common in the
mountainous region, where many parents considered
vaccine being delivered through the national health sys-
tem as their primary reason for vaccination. They
believed that they/their girls were selected to participate
in the program because the government cared for them.
“We heard people talking or saying on the loudspeaker
that it was a dangerous disease which could lead to
death if treatment did not work. Previously, we did nothave opportunity to get treatment, so we could only
foresee death. Now, the government cared for us, we
shall take our daughter to get vaccinated.”
– Parent of fully vaccinated girl, FGD, Year 2,
Mountain, hard to reach commune
This may be due to the fact that people in mountain-
ous areas, where most ethnic minorities live, receive sev-
eral special supports from the government. When a
government program is launched, they tend to partici-
pate in large numbers more so because the program is
government sponsored.
Economic benefits
While the cost of HPV vaccination was not the most
common motivation, it emerged as a theme in the
FGDs with parents of fully vaccinated girls. Particu-
larly among participants from rural areas, there was a
tendency to focus on economic benefits (an expensive
but freely-delivered vaccine). As the following quote
illustrates, they emphasized that, in the context of
high rural poverty, the free vaccine helped to increase
acceptability.
For those who are living in the rural area like us, we
are still very poor. When we were told that
vaccination helped women to prevent diseases, we
found that it was really helpful. In fact, in the rural
area, we cannot afford to take a child or a family
member to the hospital for health care services. So
when we heard that information on the loudspeaker
and even on television, we found it did bring benefits
and we took the girls to get vaccination.
– Parent of fully vaccinated girl, FGD, Year 2, Rural,
low uptake commune
However, in a larger context of vaccine acceptance, the
economic rationale was not a critical factor.
Reasons for non-acceptance of vaccination
Patterns for non acceptance of HPV vaccination
reflected in qualitative research followed three princi-
pal themes: vaccine safety and side effects, suspicion
and misconceptions about the HPV vaccine, and con-
cerns related to the age of the girl and her risk of
cervical cancer. The quote below, while touching on
vaccine safety and side effects, also shows concern
about the newness of the vaccine related to the
daughter’s perceived vulnerable age:
“Generally, I don’t need any more information.
However, I worried if there would be any side effect on
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but firstly, the vaccine is new. Secondly my daughter is
still too young so I don’t want her to receive a new
vaccine. Don’t know what will happen to her in the
future.”
– Parent of non vaccinated girl, SSI, Year 1, Urban,
low uptake commune
This quote illustrates the interconnected nature of par-
ent concerns and suggests that multiple issues may be
raised when parents are given the opportunity to discuss
their rationales in depth.
Another theme that emerged was suspicion and miscon-
ceptions about the program or vaccine, sometimes centered
on mistrust that a very expensive vaccine was being offered
free of charge and therefore may be low quality (“fake medi-
cine”), and at other times expressed as fear that children
may be part of a vaccine trial (primarily in the first year).
“. . .What that professor said significantly influenced
my decision. Working in health sector, he should be
very knowledgeable in this issue. His remarks made
me concerned, leading me to cancel the second dose
[for my daughter]. People said this vaccine is very
expensive, priority should go to relatives of ‘insiders’
who are highly ranked officers working in health
sector. Secondly, if this vaccine is good, besides the
option of having our daughter vaccinated for
protection, we also have the choice of not taking it. In
our situation, I felt some suspicion as my daughter’s
teacher mentioned about various things [about the
vaccine], scaring her. . .”
– Parent of non vaccinated girl, SSI, Year 2, Urban,
low uptake commune
“On that day, there was an official from district
and commune levels. I also asked questions, but
they gave only general answers. They could not
answer my question if this vaccine project is a trial
or not, and who would take responsibility for the
potential effects.”
– Parent of non vaccinated girl, SSI, Year 1, Rural, low
uptake commune
"If the vaccine is introduced in the whole country then
I have no objection, but why only two provinces, that is
my concern. I feared that my daughter may be used
for experiment; besides, I wonder why only children in
grade 6 but not children of other ages? That did notconvince me; maybe the vaccine is on trial and the
children are used to check the effects of vaccine.”
-Parent of non-vaccinated girl, SSI, Year 1, Urban, low
uptake commune)
Age-related concerns—exposing young adolescent girls
to HPV vaccination—were an important reason for re-
fusal among some parents. From the quote below, it
appears that not all parents understood that HPV vac-
cine has greater efficacy if administered prior to the
onset of sexual activity. From the point of view of one
mother, it was not necessary to administer HPV vaccine
at such an early age, and better to wait until the girl
reached maturity.
“From what I have read, I found that girls at this age
group have not started sexual activities, so the vaccine
would only be effective in five years. After that, the girl
should repeat doses each year. My girl is just 12 years old,
which means that she will become sexually active in the
next six years and will be exposed to the disease then. So
I decided that whenever her health is ready, I would
allow her to get vaccination. At that time, I believe that
the vaccination program is better, so I would volunteer to
take my daughter to preventive medical centers for
vaccination.”
– Parent of non-vaccinated girl, SSI, Year 2, Urban,
low uptake commune
For other parents, concerns regarding the daughter’s
age center on her perceived vulnerability, and a potential
impact on her physical development.
“In my girl’s case, she is not mature yet. She even has
not started menstruation yet. I speak so truthfully to
you because you are working in the health sector. You
know, I am afraid whether vaccination would affect
her natural development. I am afraid so I do not
allow the girl to get vaccination.”
– Parent of non-vaccinated girl, SSI, Year 2, Urban,
low uptake commune
Active and passive decision-making
Based on analysis of how parents make decisions about
HPV vaccination, we conceptualized the process as either
a passive decision or active decision according to whether
parents sought the advice of others. While the former
refers to the group of parents who made the vaccination
decision without seeking additional information, the latter
includes those who decided after consulting one or more
additional sources of information (see Figure 3).
Hear about HPV vaccination 
in the locality 
Passive decision-making 
No consult or additional 
information sought 
Active decision-making 
Consult or additional information 
sought 
Vaccinate Not vaccinate Vaccinate Not vaccinate 
Figure 3 Decision- making process for HPV vaccine acceptance.
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Our qualitative findings suggest that passive decision-
making occurred frequently during the first year of HPV
vaccine implementation, and may have occurred more
often in mountainous areas. The quote below illustrates
this passive decision-making process:
I told my daughter that this was a deadly disease, and
that my family was still in difficulty. As what was
stated in the loudspeaker, vaccination was to prevent
the girl from this disease when she grew up and got
married. If the disease did occur, we could not afford
the treatment. So it would be better if she got
vaccination to prepare for perfect health in the future
when she got married.
– Parent of fully vaccinated girl, FGD, Year 2,
Mountainous, hard to reach commune
Passive decision-making may prevail when parents
participate in the HPV vaccination as a routine response;
in the example below, vaccination is just something that
one does as a matter of course:
“. . .Immunization is the best way of prevention. Whatever
disease like tuberculosis or measles, immunization is the
best. Prevention is better than treatment.”
– Parent of fully vaccinated girl, FGD, Year 1, Rural,
low uptake communeActive decision-making
On the contrary, people in urban areas tended to engage
in more active decision-making, seeking additional infor-
mation, often from individuals or sources outside thevaccination program, as illustrated below:
“I searched in newspapers and found that although
this vaccine was new in Vietnam, its use had been
growing in many countries. So when I received the
information, I talked to my wife and came to a final
decision. I have two daughters, the older has mental
problem, so I consider health as the most important
issue for my younger girl. In South East Asia, cervical
cancer is quite common, so when there is scientific
advance in treatment, we, the parents, should create
good conditions for our child. We both decided that.”
– Parent of fully vaccinated girl, SSI, Year 1, Urban,
low uptake commune
“After the doctor said the vaccine has been
circulated in the market for everyone already and
passed the trial period, I felt more secure. Plus, my
relatives said the vaccine has been used in America
so that’s why I agreed to vaccinate my daughter.”
– Parent of fully vaccinated girl, SSI, Year 1, Urban,
low uptake commune
Media, with both positive and negative messaging,
may be particularly influential for Active Decision-
makers, as illustrated below:
“I heard from people and from the radio that this
vaccination was dangerous, and this and that bad
things and this and that bad things may happen so I
was afraid. But then my mother, mother-in-law, and
cousins urged that I should take my daughter to get
vaccinated, that we were still poor and it was a great
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should take the girl to get vaccinated for good health.”
– Parent of fully vaccinated girl, FGD, Year 2, Urban,
low uptake commune
“In my case, when my daughter brought the
vaccination invitation from school, I was also afraid. I
felt afraid as some people who got rabies vaccine
became paralytic after that. Those cases were also
shown on television. I also did not know much about
this vaccine, what kind of cancer it would prevent, so I
was afraid that it might cause side effects like rabies
vaccine. After careful consideration, I thought that for
such expensive vaccine, which was sponsored and was
developed by professional doctors and scientists would
be not harmful. So I changed my mind and allowed
the girl to get vaccinated. But at first I felt quite
confused.”
– Parent of fully vaccinated girl, FGD, Year 2, Urban,
low uptake commune
The process of active decision-making takes time,
as parents seek out additional resources and mull
over their decision, as shown below. Parents with re-
sidual concerns may also wait to observe any negative
consequences among vaccine recipients, before com-
mitting to vaccination:
“. . .at the beginning I did not allow my daughter to
receive vaccination. [However], after about a month,
her school and the local health workers patiently
invited me over to inform me about the HPV program.
The doctors and nurses were very enthusiastic. If I had
any questions or concerns or anything was unclear,
they clarified these issues very thoroughly. Besides, I
have relatives abroad who told me that where she lives
now, they provide vaccination for women at the age of
25 instead of 11 years old like in Vietnam. Then, I was
much more at ease and agreed to vaccinate my
daughter. So, in fact, my daughter received the
vaccination one month later than her friends.”
– Parent of fully vaccinated girl, SSI, Year 1, Urban,
low uptake commune
“I find that those girls who were vaccinated last year,
now they are in 7th grade and their health is still
good. Last year, a counseling group visited each
household to persuade the parents to have the girls
vaccinated. Then the parents found that their girlswere still in good health after vaccination. Thus this
year, they even took the younger sister to get
vaccinated.”
– Parent of fully vaccinated girl, FGD, Year 2, Rural,
low uptake commune
We found that parents rarely made decisions based on a
single factor. As many of the quotes from our qualitative
findings demonstrate, parents weighed a host of often
interconnected considerations. They employed various
strategies to reinforce their decision, including actively
seeking further information, getting advice from health
professionals or family members (in-country or abroad),
or waiting and following other parents’ actions. Though
some parents had unresolved concerns about side effects
and safety, even after receiving information on HPV vac-
cination, most decided to accept vaccination based on ad-
vice and information from external sources.
Discussion
In Vietnam, the EPI system has a long history of develop-
ment and has met with considerable success in reducing
the burden of vaccine-preventable diseases. Its strong
reputation contributes to a positive attitude in the popula-
tion toward vaccination in general. The Vietnam HPV vac-
cine experience suggests that NEPI has succeeded in
building trust by demonstrating the effectiveness of vac-
cination for disease prevention. We found evidence of this
in expressions of belief in vaccination in principle, and the
identification of government involvement as a rationale
for accepting vaccination. Indeed, formative research prior
to the vaccine demonstration project found that Vietnam-
ese parents, teachers, health providers, and civic leaders
voiced high levels of confidence in the government
immunization program [5,19]. For the general population
in Vietnam, governmental programs are associated with
high quality standards and rigor, so they are more likely to
participate in these governmental programs rather than in
seeking the same service from health providers in the pri-
vate sector. The delivery of HPV vaccine by commune
health center personnel and the additional involvement of
local authorities brought credibility to the program and
was a demonstration that the program was supported by
the government.
In addition to finding common themes for vaccine ac-
ceptance between the first and second years of the pro-
gram, our qualitative findings are also quite consistent
with quantitative data from parental surveys conducted
from the same vaccine demonstration projectd. LaMon-
tagne et al. found that Vietnamese parents were moti-
vated to participate in the vaccination campaign by
health rationales (92–94%), the involvement of the gov-
ernment (12–32%), the advice of health workers and
Table 3 Reasons for not participating or not participating
fully in HPV vaccination, 2009 (Adapted from [20])





Vaccine safety 33% 6%
Vaccination not good for health 32% 6%
Vaccine is new 15% 12%
Vaccine is experimental 5% 18%
Vaccine may impact fertility 12% 0%
School absenteeism (on vaccination day) 17% 12%
Not aware of program 6% 12%
Eligibility difficult to determine 2% 29%
Table 2 Reasons for HPV vaccine acceptance, parents of fully vaccinated girls, 2009–2010 (Adapted [20])
Rationales offered for acceptance Year 1 Year 2
School Health center School Health center
(n=415) (n=263) (n=285) (n=219)
Disease/infection prevention 52% 52% 76% 67%
Protection against cervical cancer 49% 44% 43% 51%
Vaccines are good for health 48% 42% 43% 44%
Combined health related rationales 92% 92% 92% 94%
Government program 20% 12% 29% 32%
Following advice of others 36% 3% 28% 19%
Vaccine is free 13% 14% 14% 14%
Knows someone who had cervical cancer 4% 4% 0% 0%
Cover et al. BMC Public Health 2012, 12:629 Page 10 of 14
http://www.biomedcentral.com/1471-2458/12/629teachers (3–36%), and to a lesser extent, by economic
considerations (13–14%) (Table 2)e [20]. Health ratio-
nales were also a strong motivator for mothers partici-
pating in an HPV vaccine intent-to-vaccinate study
recruited from a hospital in Da Nang [25]. However, this
study was done prior to the availability of HPV vaccine
in the Vietnamese market, discussed acceptance of HPV
vaccine as an individual health care-seeking decision,
and did not explore the principal role government plays
as the provider of more than 90% of all vaccinations in
the country.
While health rationales were preeminent, 12% and
20% of survey respondents in year 1 and 29% and 32%
in year 2 indicated that the program being run by the
government was a motivating factor. This survey re-
sponse pattern was particularly evident in the mountain
and rural regions, where parents were significantly more
likely to say they were influenced by the fact that it is a
government program (p<.000; data not shown). These
findings echo what we observed in the FGDs in the
mountain region, where government involvement in the
program was a strong motivating factor.
While the cost of HPV vaccination was not the most
common motivation, it emerged as a theme in the FGDs
with parents of fully-vaccinated girls, particularly among
participants from rural areas. However, formative re-
search in Vietnam found that even for non donated vac-
cine, acceptance is still high as long as the price is
affordable [5]. Moreover, analysis of year 2 survey data
by region found no geographic differences in the identi-
fication of cost factors as a rationale for vaccine accept-
ance, calling into question whether economic
considerations are more prevalent in some parts of the
country than others [20].
Rationales for not vaccinating that emerged in our
qualitative study—fear of side effects, misconceptions
and suspicions about HPV vaccine and the project, and
age-related concerns—are also echoed in results fromsurveys of parents [20]. Rationales for not participating
in the first yearf were concerns about the safety of HPV
vaccine and possible side effects (33% and 6%), concerns
about the health impacts of vaccination more generally
(32% and 6%), and worries about the newness (15% and
12%) and possibly experimental nature of the vaccine
(5% and 18%) (Table 3).
Concerns about safety and vaccine side effects are a
common refrain in HPV vaccine acceptability literature
[11,26-28] but suspicion about the vaccine and the
intentions of HPV program planners (reflected in par-
ents’ concern that children may be part of a vaccine trial)
emerged less often. In part, this reflects the preponder-
ance of studies from industrialized settings with strong
regulatory systems in place (e.g., US, UK, Australia, and
Canada). Indeed, a number of studies from developing
countries have reflected concern that HPV vaccines are
not well-tested (South Korea), concern over whom the
vaccine has been tested on (Ghana), and suspicion over
the involvement of foreign entities (India) [29-31]. Col-
lectively, these findings suggest that addressing suspi-
cions related to foreign involvement and the difference
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cine clinical trials may be crucial considerations for
HPV program planning in developing country settings.
The need to involve influential government stakeholders
in a visible fashion is another lesson learned from
PATH’s experience in Vietnam, and elsewhere [32].
While concerns about vaccine impacts on fertility
were cited by less than 10% of parents of non-
vaccinated girls, the findings from Vietnam echo
those from other studies of HPV vaccine acceptability
in developing country settings [33]. More than one
third of Chinese parents (38%) cited age as a rationale
for not vaccinating [34] and more than two thirds of
Ghanaian respondents (68%) expressed concerns
about HPV vaccine impacts on fertility [30]. Our
qualitative findings suggest that worry over the vac-
cine undermining a girl’s ‘natural development’ and
compromising her immature health status may be
connected to concerns about compromising her fu-
ture fertility. These findings suggest that formative re-
search to explore cultural perceptions of adolescent
health and development and how conceptions of ado-
lescence as a vulnerable period may impact HPV vac-
cine uptake could be beneficial in advance of vaccine
introduction. They also speak to the need for infor-
mation, education, and communication efforts that
target any perception that young female adolescents
are especially vulnerable to negative health effects
from vaccination, wherever such perceptions are
identified.
With respect to the decision-making process, we
identified many active decision-makers—parents who
sought out additional information to inform and con-
firm their vaccination decisions. Indeed, findings from
a quantitative study of vaccine acceptability showed
that more than four out of five parents reported that
they had discussed HPV vaccination with someone
prior to their decision in the first year. As the vaccin-
ation campaign matured in the second year (and
coverage rates reached 97%), there was still more
communication and discussion about the program. In
this study, 94% of surveyed respondents in Year 2
reported that they had discussed HPV vaccination
with someone prior to making a decision [20]. More-
over, active decision-makers were significantly more
likely to accept vaccination than passive decision-
makers who made a decision without discussion (data
not shown).
The high prevalence of active decision-making in Viet-
nam is quite consistent with results from the UK, where
only 14% of parents based their HPV vaccine decision
solely on information provided by the program [35].
However, that study identified a very intransigent popu-
lation of active refusers, who, the authors felt, would beunlikely to change their minds despite exposure to add-
itional information [35]. While these findings may suffer
from selectivity bias, if active refusers are more likely to
respond to the survey and attend information nights, the
findings raise intriguing questions about the ability of
vaccine campaigns to change entrenched anti-vaccine
attitudes.
The existence of ‘active refuser’ populations who be-
lieve that vaccination may have negative, long-term, and
unknown side effects is a widespread phenomenon. In
the Netherlands, resistance to polio vaccination was
sometimes based on religious conviction [36]. Highly
educated parents may resist MMR vaccine on the belief
that it ‘impairs the immune system’ [37]. Similar ‘anti-
vaccination’ attitudes have been observed among parents
with respect to HPV vaccine in Australia [38]. Indeed,
anti-vaccination attitudes were common enough among
parents in Australia that Cooper Robbins and colleagues,
employing a conceptual framework similar in many
respects to the model we use, identify ‘anti-vaccination’
as a separate decision-making state, distinct from active
and passive decision-making. Our qualitative findings, in
the context of a very high rate of vaccine uptake, par-
ticularly in the second year (97%) and among active de-
cision-makers, suggest that such entrenched anti-vaccine
(or anti-HPV vaccine) attitudes are yet to take root in
Vietnam.
Our findings about the importance of active decision-
making in a developing country setting generate several
implications. First, to maximize effectiveness, communi-
cation campaigns may need to employ a broad brush-
stroke, targeting influential figures, teachers, health
workers, and other members of the public; regardless of
any direct involvement in the program, these individuals
may influence uptake indirectly, through informal con-
sultations. The second concerns the possibility that dis-
cussion with others may quell vaccine-related concerns
and/or generate the perception of broader community
support for vaccination. Researchers may want to ex-
plore further if and how dialogue facilitates decision-
making and contributes to vaccine uptake. Third, pro-
gram planners would do well to anticipate the need for
active decision-making in the scheduling of vaccination
campaign activities by providing information well in ad-
vance of the scheduled vaccination drive.
Limitations and strengths
Our study, while robust, may have limitations that
affect the interpretation of our findings. Even though
we have tried for a diverse set of participants, because
selection was criteria-based and not random, there
could be selection bias among the participants that
may over or under-estimate the different factors men-
tioned as motivators for vaccine acceptance.
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tion of mothers and fathers, and the sex of the parent
was not available for parents of partially- or non-
vaccinated girls who participated in a semi-structured
interview. Therefore, we could not analyze our results
for possible differences between parents. However, pre-
vious research about parental decision-making for vac-
cination in Vietnam indicated that such decisions are
made jointly, suggesting that there would be a high con-
cordance between parents’ acceptability, thus reducing
the need to study mothers and fathers separately [5].
Previous HPV vaccine intent-to-vaccinate research
among Vietnamese parents by Breitkopf, et al. demon-
strated that mothers and fathers largely agreed on their
recommendation to accept or not accept a hypothetical
offer of HPV vaccine for their daughter [39].
Additionally, because so few girls overall were
partially-vaccinated and only 3% of the total popula-
tion did not accept HPV vaccine in year 2, there were
too few parents available from these groups to consti-
tute a focus group, necessitating the use of SSIs.
While the SSI approach differs from a focus group,
the SSI questionnaire content was nearly identical to
that explored through the FGD methodology with
parents of fully vaccinated girls that there may not
have been a loss in substantive content through the
two techniques. Even though our analysis utilized a
rigorous inductive and iterative process to identify
key themes and subthemes, we may have missed key
minor voices, especially from parents of partially vac-
cinated girls, which could have enriched the picture
of vaccine acceptability among parents in Vietnam.
However, we sought to minimize these limitations by
the extensive scope of our sample and thoroughness
of our FGD and interview guides with parents, allow-
ing for the broadest range of ideas to come forward
during data collection. Additionally, the qualitative re-
search methodology we employed allowed us to ex-
plore in greater depth parents’ stated reasons for
participating or not participating in the vaccination
campaign, to gain a more comprehensive understand-
ing of the decision-making process itself—an in-depth
exploration that is not necessarily possible through
fixed-response survey questions utilized by quantita-
tive techniques. Our qualitative methods complemen-
ted the quantitative surveys conducted among these
same populations and they both reinforce/affirm/con-
firm each other, reflected in the consistency of results
from both studies. Lastly, our study was able to con-
firm acceptability motivators and process by collecting
data from parents at two points in time, after each
year of vaccinations, which provided information on
how HPV vaccine acceptability may have evolved over
time as the vaccination program matured.Conclusion
Parents in Vietnam were motivated to allow their
daughters to receive HPV vaccine by health rationales
and by the involvement of the government (NEPI) in
the vaccine program. Those who declined participa-
tion were influenced by concerns for vaccine safety
and side effects, suspicions related to the newness
and possible experimental nature of the vaccine, and
concerns about negative health impacts of vaccinating
adolescent girls. Like parents in high-resource set-
tings, Vietnamese parents are active decision-makers,
frequently seeking out additional sources of informa-
tion to inform and confirm their vaccination deci-
sions. Vietnam’s HPV vaccination experience speaks
to the importance of close collaboration with the gov-
ernment to make the most of existing high levels of
trust, and to reduce suspicions about new vaccines
that are a natural component of vaccine demonstra-
tion projects. Cervical cancer continues to be a lead-
ing cause of death for women throughout the
developing world. Experiences in Vietnam should be
shared in a wider context to reduce the lag time be-
tween when a new vaccine becomes available in the
market and when it is incorporated into national
health programs in low-resource countries.Endnotes
aA separate study assessed vaccine acceptability among
girls who were eligible for HPV vaccine. Results are pre-
sented in the following document: PATH and Vietnam
National Institute of Hygiene and Epidemiology. Evalu-
ating HPV Vaccine Delivery Strategies in Vietnam. Se-
attle, Washington: PATH; 2010.
bOf the 508 total eligible girls either not vaccinated or
partially vaccinated, only 27 (5.3%) were partially vacci-
nated, which represents 0.8% of all girls who received
the first dose of vaccine. Of the 481 total eligible girls
not vaccinated in the first year, 73% resided in one urban
area that implemented school-based delivery.
cThe sex of the parent was collected only for FGD par-
ticipants, so precise distribution of mothers and fathers
is not available.
dWe occasionally cite previously published findings
from a representative survey of parents whose daughters
were eligible for HPV vaccine during a demonstration
project in Vietnam. A full description of this survey’s
methodology has been previously published (LaMon-
tagne DS et al., 2011).
eThe data in Table 2 represents the range across the
two delivery strategies (school-based and health center-
based) and program years.
fNote that we replicate here only data published on
the first year of the project, given very high coverage
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